Thema: US69353Y1038
PMVP, US69353Y1038
trading-6531134_1920.jpg - Foto: THN
PMV Pharmaceuticals stock moves above 200-day average as analysts stay mixed
PMV Pharmaceuticals stock moved above its 200-day average in the latest reported session. The clinical-stage biotech remains focused on p53-targeted cancer therapies.
ad-hoc-news.de, heute 03:27 Uhr
PMVP, US69353Y1038
PMV appoints Matt Eckler to board: 2027 filing plans matter ...
PMV reported second-quarter earnings per share of USD -0.34. PMV Pharmaceuticals stock marks a board appointment on October 1, 2026.
ad-hoc-news.de, 21.10.26 06:00 Uhr
PMVP, US69353Y1038
PMV appoints Matt Eckler: what the 2027 filing means for ...
PMV plans a first-quarter 2027 filing. Matt Eckler joined the company board on October 5, 2026, a governance milestone for PMV Pharmaceuticals stock.
ad-hoc-news.de, 16.10.26 04:32 Uhr
PMVP, US69353Y1038
PMV Pharmaceuticals adds Matt Eckler and PMV Pharmaceuticals ...
Rezatapopt reached a 46.00 percent response rate in 76 patients. PMV Pharmaceuticals stock reflects a Q1 2027 filing plan.
ad-hoc-news.de, 14.10.26 03:31 Uhr
PMVP, US69353Y1038
PMV Pharmaceuticals stock adds Matt Eckler to its board ...
PMV Pharmaceuticals stock adds a board member on October 5, 2026, as rezatapopt enrollment reaches a Phase 2 milestone. Q2 EPS beat consensus by USD 0.05.
ad-hoc-news.de, 07.10.26 00:38 Uhr
PMV, Pharmaceuticals
PMV Pharmaceuticals: Key Catalysts Approach in Q1 2026
